Shares of Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report) dropped 0.2% during trading on Thursday . The stock traded as low as $0.12 and last traded at $0.13. Approximately 312,631 shares traded hands during mid-day trading, an increase of 21% from the average daily volume of 258,226 shares. The stock had previously closed at $0.13.
Provectus Biopharmaceuticals Stock Performance
The company’s 50 day moving average price is $0.12 and its 200 day moving average price is $0.12.
Provectus Biopharmaceuticals Company Profile
Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
Featured Articles
- Five stocks we like better than Provectus Biopharmaceuticals
- What is the S&P 500 and How It is Distinct from Other Indexes
- Micron Stock Under $100: Seize the AI-Driven Upside
- Upcoming IPO Stock Lockup Period, Explained
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- How to Calculate Inflation Rate
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
